STOCK TITAN

Nevro Corp - NVRO STOCK NEWS

Welcome to our dedicated news page for Nevro (Ticker: NVRO), a resource for investors and traders seeking the latest updates and insights on Nevro.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nevro's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nevro's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.62%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
fda approval
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.59%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.13%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.34%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.74%
Tags
conferences
Nevro Corp

NYSE:NVRO

NVRO Rankings

NVRO Stock Data

524.86M
35.45M
3.9%
108.39%
11.99%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Redwood City

About NVRO

headquartered in redwood city, california, nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. nevro has developed and commercialized the senza spinal cord stimulation (scs) system, an evidence-based neuromodulation platform for the treatment of chronic pain. the senza system is the only scs system that delivers nevro's proprietary hf10 therapy. the nevro® senza® scs system received ce mark in 2010, tga approval in 2011, fda approval in 2015, and is commercially available in europe, australia, and the united states.